| Drug General Information |
| Drug ID |
D07WEU
|
| Former ID |
DNC009916
|
| Drug Name |
PURVALANOLA
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H25ClN6O
|
| InChI |
InChI=1S/C19H25ClN6O/c1-11(2)15(9-27)23-19-24-17(22-14-7-5-6-13(20)8-14)16-18(25-19)26(10-21-16)12(3)4/h5-8,10-12,15,27H,9H2,1-4H3,(H2,22,23,24,25)
|
| InChIKey |
PMXCMJLOPOFPBT-UHFFFAOYSA-N
|
| CAS Number |
CAS 212844-53-6
|
| PubChem Compound ID |
|
| PubChem Substance ID |
7437576, 8153069, 10318964, 26759425, 29224060, 47810571, 50227717, 53800571, 99302804, 104013557, 104307953, 128939094, 134340168, 134340395, 137183851, 142430781, 163126032, 163687428, 175607504, 178102652, 179148896, 204361146, 208264792, 229338079
|
| Target and Pathway |
| Target(s) |
Cell division protein kinase 2 |
Target Info |
Inhibitor |
[2]
|
|---|
| Cyclin-A2 |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
FoxO signaling pathway
|
|
Cell cycle
|
|
Oocyte meiosis
|
|
p53 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Hepatitis B
|
|
Measles
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Prostate cancer
|
|
Small cell lung cancerhsa03030:DNA replication
|
|
Base excision repair
|
|
Nucleotide excision repair
|
|
Mismatch repair
|
|
HTLV-I infection
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
p53 pathway
|
|
p53 pathway feedback loops 2
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by PRL
|
|
p73 transcription factor network
|
|
E2F transcription factor network
|
|
ATR signaling pathway
|
|
mTOR signaling pathway
|
|
IL2-mediated signaling events
|
|
FoxO family signaling
|
|
FOXM1 transcription factor network
|
|
BARD1 signaling events
|
|
p53 pathway
|
|
Regulation of retinoblastoma protein
|
|
PathWhiz Pathway
|
Nucleotide Excision Repair
|
|
Reactome
|
G0 and Early G1
|
|
Activation of ATR in response to replication stress
|
|
Regulation of APC/C activators between G1/S and early anaphase
|
|
SCF(Skp2)-mediated degradation of p27/p21
|
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
DNA Damage/Telomere Stress Induced Senescence
|
|
Processing of DNA double-strand break ends
|
|
G2 Phase
|
|
Orc1 removal from chromatin
|
|
Cyclin E associated events during G1/S transition
|
|
Cyclin A/B1 associated events during G2/M transition
|
|
p53-Dependent G1 DNA Damage Response
|
|
Cyclin A:Cdk2-associated events at S phase entry
|
|
Meiotic recombination
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-113510:E2F mediated regulation of DNA replication
|
|
Cdc20:Phospho-APC/C mediated degradation of Cyclin A
|
|
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
|
|
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
|
|
HDR through Homologous Recombination (HRR)
|
|
Dual Incision in GG-NER
|
|
Dual incision in TC-NER
|
|
Gap-filling DNA repair synthesis and ligation in TC-NER
|
|
G1/S-Specific Transcription
|
|
WikiPathways
|
DNA Damage Response
|
|
ID signaling pathway
|
|
DNA Replication
|
|
G1 to S cell cycle control
|
|
M/G1 Transition
|
|
S Phase
|
|
Meiotic Recombination
|
|
Aryl Hydrocarbon Receptor
|
|
ATM Signaling Pathway
|
|
Retinoblastoma (RB) in Cancer
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Oncostatin M Signaling Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Synthesis of DNA
|
|
Regulation of DNA replication
|
|
Mitotic G2-G2/M phases
|
|
Mitotic G1-G1/S phases
|
|
Factors involved in megakaryocyte development and platelet production
|
|
Cell Cycle
|
|
APC/C-mediated degradation of cell cycle proteins
|
|
Cell Cycle Checkpoints
|
|
miRNA Regulation of DNA Damage ResponseWP615:Senescence and Autophagy in Cancer
|
|
Mismatch repair
|
|
EGF/EGFR Signaling Pathway
|
|
Nifedipine Activity
|
|
Primary Focal Segmental Glomerulosclerosis FSGS
|
|
Nucleotide Excision Repair
|
|
Telomere Maintenance
|
|
Base Excision Repair
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6030). |
|---|
| REF 2 | Biochem J. 2007 Dec 15;408(3):297-315.The selectivity of protein kinase inhibitors: a further update. |
|---|
